FAS and urothelial carcinoma: In vitro, this bifunctional therapy (M7824) was demonstrated to increase the lysis of urothelial carcinoma cells by T cells compared to effects of anti-PD-L1, a result that was associated to the upregulation of molecules involved in immunogenic modulation (i.e., intercellular adhesion molecule 1/ICAM-1, carcinoembryonic antigen/CEA, and Fas cell surface death receptor/FAS) (Grenga et al., 2018).